However, to confirm the usefulness of PPARα agonists for the statin residual CVD risk, well-designed studies focused on subjects with metabolic syndrome or atherogenic dyslipidemia in primary and secondary prevention should be needed in the future. Here, PPARA is linked to metabolic syndrome.